It is a challenge to develop a universal single drug that can treat breast cancer at single or multiple-stage complications, yet remains nontoxic to normal cells. The challenge is even greater when breast cancer-specific estrogen-based drugs are being developed which cannot act against multi-staged breast cancer complications owing to cells' differential ER expression status and their possession of drug-resistant and metastatic phenotypes. We report here the development of a first cationic lipid-conjugated estrogenic derivative (ESC8) that kills breast cancer cells independent of their estrogen receptor (ER) expression status. This ESC8 molecule apparently is nontoxic to normal breast epithelial cells, as well as to other non-cancer cells. 
INTRODUCTION
Breast cancer drugs are often based on targeting estrogen receptors (ER) because of ER's relatively high abundance in most types of breast cancers. The status of this important biomarker provides favorable prognostic features and helps individualize breast cancer therapy (1, 2) . Several estrogen-based modulators that rely on mechanisms such as antagonism to estrogen-ER binding, ER-mediated transcription, or estrogen-based hybrid DNA-alkylating agents have been developed over time (1, (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . But adjuvant therapy is usually warranted in highly aggressive breast cancer phenotypes that are not responsive to conventional singleagent estrogen. Many other selective ER modulators (SERMs) (e.g., fulvestrant, a lipid-modified analogue of endogenous natural ligand 17 β-estradiol; the non-estrogenic molecules tamoxifen and raloxifen) were largely limited to the treatment of ER-positive breast cancer (13) (14) (15) (16) .
However, developing a universal anti-breast cancer estrogenic molecule that is nontoxic to normal cells, yet acts against both ER-positive and ER-negative breast cancers with drugresistant and metastatic phenotypes, is challenging.
Most anti-cancer, agent-mediated cancer cell killing occurs through induction of apoptosis. Apoptosis is the type I process involved in programmed cell death (PCD), the other mechanism being autophagy (type II). The ability of tumor cells to evade engagement of apoptosis plays a significant role in their resistance to conventional therapeutic regimens. Of the two major pathways of apoptosis (i.e., intrinsic or extrinsic), activation of the mitochondriaassociated intrinsic pathway leads to an increase in caspase-9 and caspase-3, resulting in apoptotic cell death (17) .
Autophagy, the self-cannibalism in cells, is often triggered for cyto-protective or survival purposes, including facilitating drug resistance in breast cancer cells and protecting cells against pro-apoptotic insults (18) (19) (20) . However, further studies also suggest a definitive role for autophagy in cancer and in determining the response of tumor cells (e.g., breast tumor cells) to anti-cancer therapy (21) . It has been shown that anti-estrogen treatment of ER-positive breast cancer cells leads to induction of autophagy (22) but to our knowledge there is no evidence of anti-estrogen-mediated involvement of autophagy in ER-negative breast cancer cells. The PI3K-Akt-mTOR signaling pathway, which negatively regulates autophagy, is involved in tumorigenic progression in many cancers and is one of the two mechanisms of induction of autophagy (23) .
In this study, we developed a cationic, lipid-conjugated, estrogenic molecule that, in contrast to other estrogenic drugs and SERMs, induced cell death in both ER-positive and ERnegative breast cancer cells. This estrogenic drug-mediated killing of ER-negative breast cancer cells prompted us to conduct an in-depth mechanistic study in ER-negative MDA-MB-231. We found that the apoptosis was induced through up-regulation of the BAX/Bcl-2 ratio, leading to activation of initiator caspase 9 and effecter caspase 3. In this study we also found that ESC8 treatment evoked the upregulation of autophagy via inhibition of the mTOR pathway and that activation of autophagy promoted the cell death of MDA-MB-231 cells. We observed a decrease in phosphorylation of mTOR at ser-2448 and a simultaneous increase in phosphorylation of Akt1/2/3 at ser-473 on ESC8 challenge. We assume that ESC8 treatment inhibited mTOR activity, thereby increasing phosphorylation of Akt in a feedback loop similar to that of rapamycin treatment. The molecule was also tested in vivo to show a significant reduction of tumor aggression. To our knowledge, this is the first example of a concomitant induction of estrogenic drug-mediated autophagy and apoptosis in breast cancer through regulation of PI3K-Akt-mTOR signaling and uncovering of this pathway, which we believe is novel, for promoting tumor cell death may have therapeutic implications in the treatment of breast cancer. 
MATERIALS and METHODS

Antibodies
Anti-caspase-3 (#9662), caspase-8 (#9746), caspase-9 (#9502), p-mTOR (#2971), mTOR (#2972), p-p70S6K (#9234), Bcl-2 (# 2876), Atg5 (#2630), Atg12 (#2010), Beclin-1 (#3738), and LC-3B (#2775) antibodies were purchased from Cell Signaling (Danvers, MA), anti-mouse β-Actin antibody was purchased from BD-Pharmingen (San Diego, CA), anti-p-Akt-1/2/3 (Ser-473) (sc-7985), anti-Akt-1 (sc-1618), anti-BAX (sc-6236), anti-Bid (sc-11423), and anti-cytochrome c (sc-13156) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Compound synthesis and characterization
A detailed synthesis of ESC8 is described in the supplementary section.
Cells and cell culture conditions
Detailed cell culture conditions have been provided in the Supplementary "Materials & Methods" section.
Isolation and maintenance of rat hepatocytes
Hepatocytes were isolated from adult male wistar rats (250 g). A detailed procedure is available in the supplemental data.
Isolation of normal human breast epithelium cells
Normal human breast epithelial cells were isolated from human normal breast epithelial tissue of donor breast cancer patient and obtained as a kind gift from Indo-American Cancer Center, Hyderabad, India. A detailed procedure is available in the supplemental data.
Preparation of samples and sample treatment
The compounds were dissolved in cell culture-grade DMSO to get a primary stock. The stock was progressively diluted with DMSO to get secondary stocks. Finally, the working concentrations of the derivatives were obtained by adding the secondary DMSO stocks in 10% fetal bovine serum containing cell culture medium. For controls, cells were treated with only DMSO containing serum-medium and volume of DMSO was equal to the volume of DMSO in which the drugs were dissolved and added to the serum containing medium before the treatment. The amount of DMSO in working solutions never exceeded more than 0.2% with respect to the serum containing culture medium. For the viability studies, 100 µl of cell culture solutions containing respective concentrations of compounds are given to cells pre-washed with phosphate buffer saline. For flow cytometric analysis, 1.5 mL of culture media containing a respective concentration of ESC8 was added to each well of six-well plates.
Cytotoxicity study
Cytotoxicities of the compounds were evaluated by the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction assay. A detailed procedure is available in supplemental data.
Annexin V staining
The annexin V-FITC-labeled apoptosis detection kit (Sigma Chemical Co., MO). was used to detect and quantify apoptosis by flow cytometry as per manufacturer's instructions. In brief, cells
(1 x 10 6 cells/well) were seeded in six-well plates and cultured overnight in 10% serum media.
The next day, cells were treated with 10 μM ESC8 for 16 hours, harvested in PBS, and collected by centrifugation for 5 minutes at 1,000 rpm. Cells were then resuspended at a density of 1 x siRNA knockdown: MDA-MB-231 cells were treated with 100 nM of control/ Atg5 siRNA using Dharmafect-1 (Dharmacon). After 48 hours cells were trypsinized and 5000 cells were plated in 96-well plates and kept overnight. Then cells were treated with either DMSO or ESC8 (5 µM) for 16 hours and cell viability assay was done as described in supplementary.
Autophagic flux Assay
Detection of autophagic flux, the specific processing of autophagy protein LC3 with or without a lysosomal protease inhibitor was determined by Western analysis. MDA-MB-231 cells were treated with or without both pepstatin A and E46d (10 μM) (24) along with ESC8 (1 or 5 μM) for 16 hours and LC3-II level was detected by western blot analysis.
Visualization of monodansylcadaverine (MDC) labeled vacuoles
MDA-MB-231 cells were grown on the cover slip, were first treated with DMSO or ESC8 (5μM) for 16 hours. Autophagic vacuoles were then labeled with MDC by incubating cells with 0.05 mM MDC in PBS for 10 minutes at 37°C. After incubation, cells were washed thrice with PBS and fixed with 3% paraformaldehyde for 15 minutes at room temperature, and again washed thrice with PBS. Cells were then permeabilized with 0.05% Triton-X for 15 minutes at room temperature, washed with PBS and followed by mounting in Vectashield (Vector Labs, CA) without DAPI. Confocal microscopy was performed using a Zeiss LSM 510 confocal laser scan microscope. Cytochrome c levels in cysolic extracts were detected by Western blot analysis.
Cytosolic Extract Preparation
Western Blot Analysis
Western blot analysis was performed to detect the levels of Bcl-2, BAX, Bid, Atg5-Atg12 complex, Beclin-1 and LC-3 expressions, Akt-1/2/3, mTOR, p70S6K phosphorylations, and caspase activation in ESC8-treated MDA-MB-231 cells. Cells were washed with PBS and lysed with RIPA buffer supplemented with a protease inhibitor cocktail after 16 hours of treatment.
Supernatant was collected by centrifugation at 13,000 rpm for 10 minutes. Samples were then subjected to SDS-PAGE and then transferred to polyvinyl difluoride membranes and immunoblotted. Antibody-reactive bands were detected by enzyme-linked chemiluminescence (Amersham, Piscataway, NJ) and quantified by laser densitometry. These experiments were repeated at least three times. MDA-MB-231 tumors were removed and fixed in neutral buffered 10% formalin at room temperature for 24 hours prior to embedding in paraffin and sectioning. Sections were deparaffinized and then subjected to TUNEL staining for apoptosis according to the manufacturer's instructions (DeadEnd TM Colorimetric TUNEL system, Promega). The TUNELpositive nuclei were counted in the entire section. Thereafter, ten fields of vision were photographed, the total number of nuclei was counted, and the average number of nuclei/unit area was calculated. Photographs of the entire cross-section were digitized using an Olympus camera (DP70). The apoptosis index was calculated as the number of positive nuclei divided by the total number of nuclei. 
Animal xenograft model
RESULTS
Synthesis and anti-cancer effect of ESC8
We synthesized ESC8 by inserting an eight-carbon (C8), twin-chain, cationic lipid at the 17β position of estradiol (ES) (Figure 1a) . Our previous study indicated that any lipid-based substitution at the cyclopentyl-ring (ring d), especially at the 17β-position, largely retains its selective ability to target ER-expressing cancer cells when associated with a liposomal delivery system (27) . The detailed synthesis of ESC8 is provided in the supplementary data. Cationic lipids containing twin carbon chains show natural affinity towards negatively-charged cellular membrane making them excellent agents to deliver bioactive molecules such as DNA inside the cells. We hypothesized that they may enhance the uptake of small molecule ligands also. In accordance with our hypothesis, co-treatment of cationic lipid moiety and estrogen induced increased toxicity in comparison to individual treatments (Figure 1b) . We also presumed that a chemical conjugation would be more effective than co-treatment due to proximity and better cooperative effect. This presumption indeed seems to be true as the conjugated moiety showed additional level of anticancer effect (Figure 1b) . In an attempt to justify our hypothesis, we tested the anti-cancer effect of ESC8, an estrogenic molecule, in different kinds of breast cancer cells. 
ER+), and MDA-MB-435S (ductal, ER-). The non-cancer cells were COS-1, CHO, freshly isolated rat hepatocytes, and normal breast epithelia (NBE, isolated from human breast cancer patients). Figure 1e clearly shows that ESC8 induced killing of all breast cancer cells but was unable to induce toxicity to any of the normal or healthy cells at the treated concentration.
Moreover, use of ER-antagonist, ICI182780, was able to abrogate the anti-cancer effect of ESC8 in ER-positive MCF-7 cells but had no effect in ER-negative MDA-MB-231 (Figure 1f) . Therefore, ESC8-mediated toxicity via ER-antagonism can be ruled out for MDA-MB-231. In conclusion, ESC8 was clearly the most potent anti-cancer agent in comparison to other breast cancer-specific estrogenic, non-estrogenic, and ER-antagonizing molecules and -most importantly -ESC8 induced killing of these cells irrespective of ER-expression status.
ESC8 induces apoptosis in breast cancer cells
To ascertain the induction of apoptosis in cancer cells following ESC8 treatment, we first studied 
ESC8 induces autophagy
The role of autophagy in cancer is a topic of intense debate. Many anti-cancer agents have been reported to induce autophagy, suggesting tumor cell death by these agents (21) . As a matter of interest, we chose to see if ESC8 also falls in the above-mentioned category of agents that induce autophagy as a mediator of cancer cell death. As part of our investigation, we Taken together, our data (Figure 2-3) indicated that ESC8 led to simultaneous induction of apoptosis and autophagy to kill the ER-negative breast cancer cells. Finally, we wanted to understand which pathway might be involved in this regulation.
Effect of ESC8 on Akt and mTOR phosphorylation
The P13K/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR)-signaling pathways has been implicated in autophagy and apoptosis regulation (31) (32) (33) . 
DISCUSSION
Breast cancer, the leading cause of death in women worldwide, is associated with ER and its functional activity in 60% to 70% of cancer cases. Conventional treatments of early-stage or ERresponsive advanced-stage breast cancer rely on either hormone ablation or antagonizing ER through the use of small molecule drugs. The use of conventional therapeutics for advanced breast cancer becomes wasteful, non-effective and, in some cases, exacerbates the situation through the induction of thrombosis and endometrial carcinoma -especially for tamoxifentreated cases (34, 35) .
The complexity in the advanced or post-ER-reliance stage of cancer, which includes the failure to activate apoptotic signals, heralds the transformation of primary cancer cells into a drug-resistant, metastatic phenotype. In a recent study, we could selectively manipulate glucocorticoid receptor (GR), a nuclear hormone receptor (NHR), in cancer cells using a cationic liposomal formulation associated with GR-ligand dexamethasone for selective access to the GR response element in cancer cells' nuclei (36) . In trying to replicate a similar observation with breast cancer cell-associated NHR, ER using its endogenous ligand, ES, we found to our surprise that ES in mere association with an eight-carbon, twin-chain, quaternary ammonium cationic lipid could efficiently kill both ER-positive and ER-negative breast cancer cells.
On the basis of the above observations, we hypothesized that instead of mere association, if we chemically conjugate this eight-carbon cationic lipid to an estrogen molecule, we might get enhanced anti-breast cancer activity. We found that ESC8 could initiate ER expression-status nonspecific, anti-breast-cancer activity, but with minimal toxicity to the non- Our subsequent studies revealed ESC8-mediated prominent induction of apoptosis in both ER-positive and ER-negative cancer cells. On investigating the specific reason for the activation of apoptosis in ER-negative MDA-MB-231 cells, we found significant apoptosis induction through the mitochondria-mediated intrinsic pathway in which caspase 3 formation was triggered by an elevated level of caspase 9 on ESC8 treatment. We also noticed that autophagy was highly induced but with no significant change in the level of autophagy-related proteins such as Atg5-Atg12 and Beclin-1. Because one of the autophagy regulators is the PI3K-Akt-mTOR pathway, we investigated the effect of ESC8 on the protein levels of p-Akt-1/2/3 (ser-473), p-mTOR (Ser-2448), and p-p70S6K (Thr-389). ESC8 treatment inhibited mTOR and p70S6K phosphorylations, however we observed an increase in phosphorylation of Akt at ser-473 with the 10 μM dose of ESC8. Although increased Akt phosphoryation is pro-survival, this finding resembles the rapamycin-mediated mTOR inhibition, which accompanies elevation of the phospho-Akt level in a negative feedback loop. Previous literatures have shown that rapamycin-induced Akt phosphorylation is dependent on PI3K and IGF signaling pathway (37, 38) . Therefore, mTOR is a possible target of ESC8 and we think that ESC8 in combination with Akt Inhibitor would be better option for breast cancer therapy. Additional in-depth studies are currently being done to further look into the novel mechanism.
Our observation of simultaneous induction of mitochondria-assisted apoptotic signal and autophagy induction followed by inhibition of mTOR activity contradicts the previous literature, which showed that inhibition of mTOR fortifies cells against pro-apoptotic stimuli with the concomitant induction of autophagy (18, 19) . Here in ESC8-mediated killing of breast cancer cells, autophagy accompanies apoptosis, and our data also clearly prove that under these circumstances, the induction of autophagy is not cytoprotective in nature. In conclusion, we report the development of a new class of highly efficient anti-breast cancer agents that contain a novel combination of estradiol and cationic lipid moieties. This estrogenic molecule, in contrast to other available estrogenic drugs, exhibits highly efficient anticancer activity in all ER-positive and ER-negative primary and advanced breast cancer cells.
Hence, this anti-cancer agent is the first estrogenic drug that, with this special chemicostructural trait, shows unusual co-induction of autophagy and apoptosis in that it kills even ERnegative breast cancer cells. This unique structural trait provides the potential scope to treat even multiple-staged breast cancer using a single drug-based therapy. 
